The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day

WASHINGTON, D.C. – February 14, 2018

The Alliance for Regenerative Medicine (ARM) today announced its annual Cell & Gene Therapy Investor Day will take place April 17, 2018 in New York City. This annual meeting provides institutional, strategic, and venture investors with unique insights into financing opportunities for cell and gene therapy-based treatments and tools.

This year’s event will include clinical and commercial experts addressing the outlook for these products, and how this sector is impacting key therapeutic areas, including oncology, cardiovascular disease, ophthalmology, rare diseases, diabetes, wound healing, tissue repair, and neurodegenerative diseases. The program also includes talks by key opinion leaders in the industry, analysts closely following the sector, as well as presentations by more than 30 of the most promising companies in the field.

“With a growing number of products on the market and continual clinical successes, this field is attracting greater investor and analyst interest,” said Janet Lambert, ARM CEO. “With a robust pipeline and dozens of products poised for commercial launch in the short term, there remains significant investment opportunities for investors to finance the next wave of medical breakthroughs.”

Initial Slate of Presenting Companies:
4D Molecular Therapeutics, Adaptimmune, Adverum Biotechnologies, AGTC, AVROBIO, BioCardia, bluebird bio, B-MoGen Biotechnologies, BrainStorm Cell Therapeutics, Capricor Therapeutics, Celixir, Cynata Therapeutics, Fibrocell, Frequency Therapeutics, Histogenics, Iovance Biotherapeutics, Kiadis Pharma, LogicBio, Lysogene, Miromatrix, Orchard Therapeutics, Oxford BioMedica, Precision Biosciences, ReNeuron, Sernova Corp, Synpromics, Tmunity Therapeutics, TxCell, and Vericel

Additional companies and the program’s complete agenda will be announced shortly.

This year’s sponsors include Cryoport; CTI Clinical Trials; Kawasaki; KBI Biopharma; Lonza; and PCT, a Hitachi Group company.

For more information please visit the event’s website at Attendance is complimentary for credentialed investors and members of the media, however RSVP is required. Paid attendance is available, but is offered at the discretion of ARM. Please indicate interest in attending here.

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit

# # #